Akebia Therapeutics, Inc.
AKBA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.32 | 0.09 | 0.02 | 0.03 |
| FCF Yield | -10.15% | -10.06% | -69.47% | -67.46% |
| EV / EBITDA | -39.19 | -35.53 | 37.56 | -1.90 |
| Quality | ||||
| ROIC | -33.77% | -27.89% | -30.68% | -71.36% |
| Gross Margin | 60.56% | 61.90% | 92.31% | 61.50% |
| Cash Conversion Ratio | 0.59 | 0.45 | 0.79 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -18.18% | -2.76% | -0.24% | -14.19% |
| Free Cash Flow Growth | -74.02% | 68.08% | 71.04% | -128.56% |
| Safety | ||||
| Net Debt / EBITDA | -9.97 | -7.41 | 3.05 | 0.07 |
| Interest Coverage | -2.78 | -7.67 | -5.15 | -13.27 |
| Efficiency | ||||
| Inventory Turnover | 3.89 | 4.73 | 1.04 | 2.22 |
| Cash Conversion Cycle | 84.46 | 78.88 | 107.82 | 102.57 |